To 10X & Beyond, AgentV™-DSP Arrives Ready to Rock
Now Amping Up QuickShip™-DSP After Elvis’s 1958 departure for Army duty and a tragic plane crash in 1959, a musical cool season was felt by many who remember it. Did ... More
RoosterBio
The Spirit of MISEV
Listen to this Blog: Your browser does not support audio. To Empower, Not Haunt Investigators of Extracellular Vesicles (EVs), Exosomes, Microvesicles, & Extracellular Particles Some in the extracellular vesicle/exosome ... More
RoosterPubs in 2024 & Beyond: Catalyzing Bio-Research to “Publish & Flex”
Above, a word cloud generated by ChatGPT 4o (openai.com) using input from RoosterBio-attributing publications’ abstracts and titles from 2024. For those with limited experience in this arena, it might be ... More
Winners of RoosterBio’s 2024 Development Award
Mesenchymal stem cells (MSCs) and their derivatives are a critical raw material for a growing number of emerging advanced therapeutic applications, including engineered cell and gene therapies, engineered tissues, combination ... More
Analytics: A Referee for the Tug-of-War Between MSC-EVs’ Nature & Nurture
Ensuring safety, efficacy, and consistency in biologics like MSCs and EVs requires robust analytical methods to meet regulatory standards and deliver reliable therapies to patients. Through a phase-appropriate approach, early ... More
Cytiva & RoosterBio’s Collaboration Yields Breakthroughs to Make Exosome Manufacture Easier from Benchtop to Bedside
A Blog Summary of a Webinar Presentation by Dr. Michael Budiman, Downstream Application Leader at Cytiva, and Dr. Elie Zakhem, Senior Manager of Process Development at RoosterBio. Exosomes and/or extracellular ... More
EVs Answer to the CAR-Tease: Targeted Exosomes to Speed Toward Next-Gen Immunotherapies
Chimeric antigen receptors (CARs) displayed on extracellular vesicles and/or exosomes (EV-CARs) could offer a cell-free, scalable alternative to CAR-T therapies, with fewer side effects such as cytokine release syndrome (CRS). ... More
AgentV’s Virtues at the Vanguard of Extracellular Vesicles
“V” for Value Emerging new therapeutic agents based on extracellular vesicle and/or exosome modalities can offer great hope against unmet clinical needs. [1, 2, 3, 4, 5, 6] Nevertheless, it’s ... More
MSCs vs. Cancer — Armed with a Better Sword, the Crab Loses
As the basis for safe use in over 1,000 worldwide clinical trials targeting all broad disease indications, [1] mesenchymal stem/stromal cells (MSCs) have nevertheless been likened to a double-edged sword. ... More
Extracellular Vesicles (EVs) from Fully “Charged” MSCs Treat Advanced Cellular Models of Liver Fibrosis
Blog Summary of a Webinar Presentation by Dr. Stefania Bruno, U. Torino Fibrotic disease processes combine into a major unmet medical need, hefting an oversized burden on people suffering from ... More